# Effect of Azilsartan on Atrial Fibrillation in Patients With Hypertension

Study · id `cardio:ct-nct05841654` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT05841654](<https://clinicaltrials.gov/study/NCT05841654>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT05841654

Browse, organ or system: Heart; Blood vessels  
Browse, condition area: High blood pressure; Stroke; Heart rhythm problems  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 400 participants.

## Technical summary

Registry record NCT05841654. Randomized; single masking; primary purpose prevention. Start 2023-06-01 (anticipated); primary completion 2025-06-01 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; single masking; primary purpose prevention
- Phase: Phase 4
- Enrolled: 400 participants (planned count; ClinicalTrials.gov record NCT05841654, source copy `cardio:ctgov-nct05841654-2023-05-03`, retrieved 2026-10-26)
- Planned start: 2023-06-01 (anticipated) (ClinicalTrials.gov record NCT05841654, source copy `cardio:ctgov-nct05841654-2023-05-03`, retrieved 2026-10-26)
- Primary completion: 2025-06-01 (anticipated) (ClinicalTrials.gov record NCT05841654, source copy `cardio:ctgov-nct05841654-2023-05-03`, retrieved 2026-10-26)
- Completion: 2025-10-01 (anticipated) (ClinicalTrials.gov record NCT05841654, source copy `cardio:ctgov-nct05841654-2023-05-03`, retrieved 2026-10-26)
- Countries: China (ClinicalTrials.gov record NCT05841654, source copy `cardio:ctgov-nct05841654-2023-05-03`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct05841654-2023-05-03`, retrieved 2026-10-26)

## The registry's words

- Brief title: Effect of Azilsartan on Atrial Fibrillation in Patients With Hypertension
- Acronym: AZAF
- Condition: Hypertension
- Condition: Atrial Fibrillation
- Intervention (Drug): Azilsartan or antihypertensive drugs other than ACEI, ARB or ARNI
- Lead sponsor: Beijing Tsinghua Chang Gung Hospital
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Arrhythmia (heart rhythm problems) (`cardio:arrhythmia`)
- Registry condition terms include this condition: Atrial fibrillation (AF) (`cardio:atrial-fibrillation`)
- Registry condition terms include this condition: Hypertension (high blood pressure) (`core:hypertension`)

## Provenance

Content hash: 6b765f27b93cb291f6b406998e774bf4e135894e76ba8c8ceeba921a1b897d9c
Last substantive edit: 2026-10-26
Evidence last checked: Not recorded
